Italia markets close in 29 minutes
FTSE MIB
33.565,91 -141,30 (-0,42%) Dow Jones
39.065,89 -46,27 (-0,12%) Nasdaq
17.750,08 +32,43 (+0,18%) Nikkei 225
39.667,07 +493,92 (+1,26%) Petrolio
80,33 -0,50 (-0,62%) Bitcoin EUR
57.806,84 +3,36 (+0,01%)
NBIX Jul 2024 155.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 10:33AM EDT. Mercato aperto.
| Chiusura precedente | 1,1500 |
| Aperto | N/D |
| Denaro | 0,2500 |
| Domanda | 1,0500 |
| Prezzo d'esercizio | 155,00 |
| Scadenza | 2024-07-19 |
| Min-Max giorno | 1,1500 - 1,1500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.